Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study will examine safety and efficacy of Lapatinib in combination with a standard
neoadjuvant chemotherapy including 5FU, Epirubicin, Cyclophosphamide and Paclitaxel. Tumor
tissue will be obtained at 3 timepoints (optional 4th) to evaluate tumor response to
treatment.